Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 14/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.38 |
| ▸ | KHK | P50053 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185088 | 0.99 | ESR1 (0.42) | ESR1PDE4APDE4BPDE4DPDE4C | |
| Bromide SCHEMBL7526402 | 0.97 | ESR1 (0.41) | ESR1PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL682469 | 0.97 | ESR1 (0.38) | ESR1PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL3167730 | 0.83 | PDE4A (0.41) | ESR1PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2144178 | 0.82 | MAPK1 (0.39) | PDE4APDE4BPDE4DPDE4CKHK | |
| SCHEMBL6796557 | 0.82 | PTGDR2 (0.47) | ESR1PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL682826 | 0.81 | ESR1 (0.43) | ESR1 | |
| SCHEMBL3602939 | 0.81 | ESR1 (0.41) | ESR1PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL27426835 | 0.81 | PDE4A (0.48) | ESR1PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL27552667 | 0.81 | ESR1 (0.41) | ESR1PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1422849-A | indazole derivatives | PFIZER (US) | 2003-06-11 | — | — | CN | claimed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-0816357-B1 | Substituted indazole derivatives | PFIZER (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6262040-B1 | Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) | PFIZER INC | 2001-07-17 | — | — | US | disclosed |
| WO-2001047915-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
| US-6211222-B1 | Substituted indazole derivatives and related compounds | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| CN-1281441-A | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PFIZER PROD INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6127398-A | Substituted indazole derivatives and related compounds | PFIZER INC (US) | 2000-10-03 | — | — | US | disclosed |
| US-6040329-A | Substituted indazole analogs | PFIZER INC (US) | 2000-03-21 | — | — | US | disclosed |
| CN-1234031-A | Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the prodn. of tumor necrosis factor (TNF) | PFIZER (US) | 1999-11-03 | — | — | CN | disclosed |
| US-5958953-A | Substituted indazole derivatives | PFIZER INC (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0816357-A1 | Substituted indazole derivatives | PFIZER INC. (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | ESR1 3682/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.